Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK2 | Q92630 | 1/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 6/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25505855 | 1.00 | DYRK2 (0.37) | DYRK2PDE7ACA12CA1CA2 | |
| SCHEMBL24156909 | 0.79 | — | — | |
| SCHEMBL25505857 | 0.78 | DDB1 (0.36) | CA1CA2CREBBPMEN1KMT2A | |
| SCHEMBL25506132 | 0.77 | CREBBP (0.41) | CREBBPBRPF1 | |
| SCHEMBL25505543 | 0.76 | CREBBP (0.53) | CREBBPIDO1BRPF1RAB9AMEN1 | |
| SCHEMBL15243711 | 0.76 | CREBBP (0.58) | DYRK2PDE7ACA12CA1CA2 | |
| SCHEMBL14765190 | 0.76 | CREBBP (0.58) | DYRK2PDE7ACA12CA1CA2 | |
| SCHEMBL25509424 | 0.70 | CREBBP (0.50) | CREBBPIDO1BRPF1RAB9AMEN1 | |
| SCHEMBL2801592 | 0.65 | CDK5 (0.41) | PDE7ACA12CA1CA2CA4 | |
| SCHEMBL23728885 | 0.64 | AHR (0.40) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136607-A1 | PAD4 INHIBITORS AND USE THEREOF | REGOR PHARMACEUTICALS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4433477-A1 | PAD4 INHIBITORS AND USE THEREOF | Regor Pharmaceuticals, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-118679162-A | PAD4 inhibitors and uses thereof | 锐格药业公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2023083365-A1 | PAD4 INHIBITORS AND USE THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136607-A1 | PAD4 INHIBITORS AND USE THEREOF | PADI4, PADI6, PADI2 | DYRK2 1190/4885PDE7A 21/4885CA12 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.